骨髓纤维化患者造血细胞移植前脾照射:一项全球协作分析
这项全球协作分析纳入59例骨髓纤维化患者,在造血细胞移植(HCT)前中位2周接受脾照射,97%(57/59)患者脾脏显著快速缩小,中位缩小5.0 cm(95%CI 4.1-6.3 cm),最常见不良事件为血小板减少,3年总生存率62%(95%CI 48%-76%),1年非复发死亡率26%(95%CI 14%-38%),倾向评分匹配后脾照射与显著降低复发相关(p=.01)。
要点
- HCT前中位2周脾照射使97%(57/59)患者脾脏显著快速缩小,中位缩小5.0 cm(95%CI 4.1-6.3 cm)。
- 最常见不良事件为血小板减少,照射剂量与血液学毒性无相关性。
- 倾向评分匹配后脾照射与显著降低复发相关(p=.01),3年复发率脾照射12% vs 立即HCT 29% vs 脾切除38%。
核心结论
- HCT前立即脾照射对JAK抑制失败的骨髓纤维化患者是合理方法,且与低复发率相关。
研究设计与样本
- 全球协作分析,纳入59例接受脾照射后行HCT的骨髓纤维化患者,照射距HCT中位2周(范围0.9-12周)。
主要发现
- 照射前中位脾脏大小23 cm(范围14-35),脾照射使97%(57/59)患者脾脏显著快速缩小,中位缩小5.0 cm(95%CI 4.1-6.3 cm)。
- 最常见不良事件为血小板减少,照射剂量与血液学毒性无相关性。
- 3年总生存率62%(95%CI 48%-76%),1年非复发死亡率26%(95%CI 14%-38%)。
- 生存的独立预测因素为照射前重度血小板减少和贫血、移植特异性风险评分、更高强度预处理以及存在门静脉血栓。
- 倾向评分匹配校正常见混杂因素后,脾照射与显著降低复发相关(p=.01),3年复发率脾照射12% vs 立即HCT 29% vs 脾切除38%。
临床怎么用
- 作者认为,对JAK抑制失败的骨髓纤维化患者,HCT前立即脾照射是合理方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor graft function. Strategies to reduce spleen size before HCT especially after failure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field. Here, we leveraged a global collaboration to investigate the safety and efficacy of splenic irradiation as part of the HCT platform for patients with myelofibrosis. We included 59 patients, receiving irradiation within a median of 2 weeks (range, 0.9-12 weeks) before HCT. Overall, the median spleen size prior to irradiation was 23 cm (range, 14-35). Splenic irradiation resulted in a significant and rapid spleen size reduction in 97% of patients (57/59), with a median decrease of 5.0 cm (95% confidence interval, 4.1-6.3 cm). The most frequent adverse event was thrombocytopenia, with no correlation between irradiation dose and hematological toxicities. The 3-year overall survival was 62% (95% CI, 48%-76%) and 1-year non-relapse mortality was 26% (95% CI, 14%-38%). Independent predictors for survival were severe thrombocytopenia and anemia before irradiation, transplant-specific risk score, higher-intensity conditioning, and present portal vein thrombosis. When using a propensity score matching adjusted for common confounders, splenic irradiation was associated with significantly reduced relapse (p = .01), showing a 3-year incidence of 12% for splenic irradiation versus 29% for patients with immediate HCT and 38% for patients receiving splenectomy. In conclusion, splenic irradiation immediately before HCT is a reasonable approach in patients experiencing JAK inhibition failure and is associated with a low incidence of relapse.
引用
- Gagelmann N, Hobbs GS, Campodonico E, et al. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol. 2024. PMID: 38357714. doi:10.1002/ajh.27252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。